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a-Synuclein (aSyn) is a 140-residue amyloid-forming protein whose aggregation is
linked to Parkinson’s disease (PD). It has also been found to play a critical role in
the immune imbalance that accompanies disease progression, a characteristic that
has prompted the search for an effectiveaSyn-based immunotherapy. In this study,
we have simultaneously exploited two important features of certain heat-shock
proteins (HSPs): their classical ‘‘chaperone’’ activities and their recently discovered
and diverse ‘‘immunoactive’’ properties. In particular, we have explored the
immune response elicited by immunization of C57BL/6 mice with an aSyn/Hsp70
protein combination in the absence of added adjuvant. Our results show
differential effects for mice immunized with the aSyn/Hsp70 complex, including a
restrained aSyn-specific (IgM and IgG) humoral response as well as minimized
alterations in the Treg (CD4þCD25þFoxp3þ) and Teff (CD4þFoxp3") cell
populations, as opposed to significant changes in mice immunized with aSyn and
Hsp70 alone. Furthermore, in vitro-stimulated splenocytes from immunized mice
showed the lowest relative response against aSyn challenge for the ‘‘aSyn/Hsp70’’
experimental group as measured by IFN-g and IL-17 secretion, and higher IL-10
levels when stimulated with LPS. Finally, serum levels of Th1-cytokine IFN-g and
immunomodulatory IL-10 indicated a unique shift toward an immunomodulato-
ry/immunoprotective phenotype in mice immunized with the aSyn/Hsp70
complex. Overall, we propose the use of functional ‘‘HSP-chaperoned amyloid/
aggregating proteins’’ generated with appropriate HSP-substrate protein combi-
nations, such as the aSyn/Hsp70 complex, as a novel strategy for immune-based
intervention against synucleinopathies and other amyloid or ‘‘misfolding’’
neurodegenerative disorders.
Introduction
a-Synuclein (aSyn) is a highly conserved, soluble protein
which is abundant in various regions of the brain, and which
is currently believed to play a role in modulating synaptic
plasticity, neurotransmitter release, and presynaptic vesicle
pool size [1–3]. However, the aberrant misfolding and
aggregation of this protein and, ultimately, its conversion
into insoluble amyloid-like fibrils, are linked to Parkinson’s
disease and other synucleinopathies [4]. These and other
‘‘misfolding/conformational’’ disorders are characterized by
conversion of an initially soluble and functional polypeptide
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into aggregation intermediates to ultimately produce
insoluble aggregates that can be structurally amorphous or
fibrillar [5]. In each particular disorder, unfolding and/or
misfolding of specific proteins (for simplicity, herein referred
to as ‘‘aggregating proteins’’) are key initial steps in the
aberrant aggregation and amyloid formation process [6].
Like many of the peptides and proteins that are involved
in the most common misfolding and amyloid diseases –
including Alzheimer’s, Huntington’s, type II diabetes, and
spongiform encephalopathies – aSyn is an intrinsically
disordered protein (IDP) in its free soluble form [6]. IDPs
are a group of polypeptides that lack significant secondary
and tertiary structure, as well as many specific intra-chain
interactions [7]. The high degree of conformational
flexibility in IDPs has been suggested to underlie the
observations that these proteins upon immunization tend to
produce weak immune responses [8] and that they help
certain pathogens escape immune detection by the host [9].
In the last decade, a link has been established betweenaSyn
and the abnormal immunological process that accompanies
the onset and progression of synucleinopathies [10, 11]. In
addition to a robust microglia activation and sustained
neuroinflammation in the brain, changes in the T cell-
mediated immunity in the brain and the periphery –
including an increased presence of T effector (Teff) memory
cells and dysfunctional regulatory T (Treg) cells – are seen
during PD progression [12]. In the case of the synucleino-
pathies, several studies performed in animal models have
found that CD4þ T cells are critically involved in the
neurodegenerative and neuroprotective antagonistic pro-
cesses associated to disease [13–17]. Based on this evidence, it
has been proposed that identifying modulators that are
able to restore the imbalance in the Treg-/Teff-mediated
immunity and to induce a regulated, ‘‘neuroprotective’’
immunological environment, might be the key for develop-
ing effective immunotherapeutic strategies against neurode-
generative disorders [16, 18, 19].
Several studies carried out following the pioneering work
by Masliah et al. [20] have explored different types of
approaches to immunization with a-synuclein in animal
models, which have produced promising albeit mixed results,
or with as yet uncharacterized therapeutic efficacy in human
subjects [13, 14, 20–24]. Therefore, the development of novel
aSyn-based vaccination strategies for synucleinopathies and
related disorders stands as a highly attractive but challenging
avenue for research and development.
In addition to the long-established chaperoning functions
of heat-shock proteins (HSPs) including binding to,
remodeling, and conformational stabilization of, unfolded/
misfolded client polypeptides [25], certain HSPs have been
increasingly reported to play diverse roles as modulators of
the innate and adaptive immunity [26–29]. Such functions
range from promoting antigen cross-presentation and the
maturation of dendritic cells, to exerting immunosuppressive
signals, or facilitating the activation of lymphocytes and
macrophages [30–33].
Therefore, HSPs possess two highly valuable features that
could be simultanously exploited for aggregating protein-
based manipulation of the immune response against
misfolding or amyloid disorders, namely, their classical
‘‘chaperone’’ functions combined with their recently
discovered ‘‘immunoactive’’ properties. Indeed, this second
property has been used to boost the antibody production by
immunizing mice with DnaK (bacterial) HSP chemically
cross-linked with Ab peptide [34] and PrP protein [35], and
with a 17-aminoacid sequence from Hsp60 conjugated to an
Ab epitope [36], that is by utilizing either inactivated HSP
proteins or HSP short fragments, as carriers. Still, to the best
of our knowledge, no comprehensive characterization of the
immune response elicited by an ‘‘HSP-chaperoned aggre-
gating protein’’ complex – that is a complex generated with a
‘‘functional chaperone’’ able to interact productively with
the aggregating protein substrate and display its full
biological activities – has thus far been reported. In this
study we decided to investigate, as a proof-of-concept, the
immune response elicited by immunization with a complex-
forming HSP-aSyn combination. We took advantage of the
acquired knowledge on Hsp70, a highly conserved HSP [37],
which has been shown to bind to aSyn aggregation
intermediates [38–41] and to interact with aSyn mono-
mers [40]. We report a differential immunological profile as
a result of immunizing naive mice with a combination of
highly purified human Hsp70 and a-synuclein proteins in
the absence of added adjuvant.
Materials and Methods
a-Synuclein and Hsp70 protein overexpression,
purification, and characterization
Human Wt aSyn was over-expressed in Escherichia coli
BL21(DE3) cells using pT7-7 plasmid and purified as
described previously [42]. The purity and monomeric state
of the aSyn protein preparation (>95%) were assessed by
15% SDS-PAGE, 4–12% native PAGE (Lonza, Basel,
Switzerland), and mass spectrometry (not shown), as
previously described [42]. Recombinant N-hexa-His-tagged
human Hsp70 (HSPA1A), which was previously cloned into
the pET28b vector (Novagen, Merk Millipore, Darmstadt,
Germany) was overexpressed in E. coli BL21(DE3) (Lucigen,
Middleton, WI, USA) and then purified and treated as
described previously [40]. The purity of the Hsp70
preparation (>95%) was assessed by 12% SDS-PAGE.
After passing the protein solution through a Amicon
Ultra-100 kDa (Merck Millipore Ltd., Carrigtwohill, IRL),
the protein was assayed for its endotoxin content by the
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ToxiSensor Chromogenic LAL Assay Kit (GenScript, Piscat-
away, USA). The endotoxin levels of the protein preparations
were <1 EU/mg protein in all cases. Protein concentrations
were determined by means of Micro BCA Reagent Kit
(Pierce, Rockford, IL, USA).
Preparation of the aSyn/Hsp70 complex
In order to favor the formation of the aSyn/Hsp70 complex,
the purifiedaSyn andHsp70 proteins were pre-incubated at a
1:1 molar ratio in ‘‘Hsp70 buffer’’ (50mM Tris/HCl pH 7.4;
150mM KCl, 2mM MgCl2) in the presence of 4mM
adenosine 50-triphosphate magnesium salt (ATP) (Sigma–
Aldrich, St. Louis, USA) for two hours at room temperature
(RT), after which time adenosine 50-diphosphate monop-
otassium salt dehydrate (ADP) (Sigma–Aldrich St. Louis,
USA) was added to a 2.5mM final concentration and incu-
bated for a further two hours at RT. Sample preparations
consisted of aSyn alone, Hsp70 alone, a mixture of both, or
Hsp70 buffer, and they all contained the same buffer and
received the same incubation treatment. For immunization
purposes, samples were diluted accordingly in PBS after
incubation.
Western blot assay for aSyn/Hsp70 complex
characterization
In order to assay the formation of the aSyn/Hsp70 complex,
protein preparations were loaded onto a 4–12% native PAGE
(Lonza, Basel, Switzerland) and subjected to electrophoresis
at 120V, and transferred for 45min onto 0.2mm nitrocellu-
lose membrane (GE Healthcare, Buckinghamshire, UK).
After blocking overnight with 5% skimmed milk in PBST
(0.05% Tween 20 in PBS), the membranes were probed with
the mouse anti-a/b-synuclein (N19) polyclonal antibody
(Santa Cruz Biotechnology Inc. Heidelberg, Germany) or the
anti-Hsp70 monoclonal antibody (C96F3-3) (Enzo Life
Sciences inc. Farmingdale, NY, USA). HRP-conjugated anti-
goat (Santa Cruz Biotechnology inc. Heidelberg, Germany)
and anti-mouse (Promega, Madison, WI, USA), secondary
antibodies were used to visualize blots by using Immobi-
lionTM Western Chemiluminiscent HRP Substrate (Milli-
pore, Billerica, MA, USA) and AmershamHyperfilmTM ECL
(GE Healthcare, Buckinghamshire, UK).
Surface plasmon resonance detection of
a-synuclein-Hsp70 interaction
Surface plasmon resonance experiments were performed
in a Biacore X100 instrument with a CM5 sensor chip
(GE Healthcare). 50 nM Hsp70 (ligand) was immobilized
through the amine coupling chemistry, as follows. Both flow
cells were activated for 7min with a 1:1 mixture of 0.1M
N-hydroxysuccinimide (NHS) and 0.4M 3-N,N-dimethyla-
mino (EDC) at a flow rate of 5mL/min. Immobilization was
performed in sodium acetate buffer (pH 5.0). The ligand
(originally in a solution in ‘‘Hsp70 buffer’’) was injected at
5mL/min in 10mM sodium acetate buffer (pH 5.0) at a
concentration of 480nM on the activated sensor surface
2 (Fc2) and then 1M ethanolamine-HCl (pH 8.5) was added
to block the unreacted N-hydroxysuccinimide groups. The
level of immobilized ligand was 3173 response units (RU).
The sensor surface 1 (Fc1) was activated/deactivated without
ligand for its use as reference surface for subtraction of non-
specific signal effects. The running buffer for all the experi-
ments was 1# PBS supplemented with 0.05% Surfactant P20,
2mM MgCl2, and 2.5mM adenosine 5
0-triphosphate
disodium salt (ATP). All samples were diluted in running
buffer at 0, 20, 40, 80, 160, and 320mM, in increasing con-
centrations order with at least one duplicate of lower con-
centration after the highest analyte concentration. Contact
time for binding and dissociation time were 300 sec. All the
binding cycles were performed at 158C. No regeneration was
applied to the sensor surfaces as sensorgrams readily returned
to the baseline in the dissociation phase. An extra wash with
running buffer was applied at the end of each cycle.
Interaction data were analyzed using the Biacore X100
Evaluation Software (GE Healthcare). The equilibrium
dissociation constant (KD) was calculated from steady-state
sections of the curves 5 sec before analyte injection stop, by
using the Affinity Wizard tool.
Animals
Six to seven week old, C57BL/6 male mice were purchased
from the University of Seville Center for Animal Production
and Experimentation (Espartinas, Spain). Animals were kept
for one week in the local animal house before the start of the
immunization protocol, to allow the mice to acclimatize to
their new environment. At all stages of the study, animals
from each experimental group were allocated into different
cages such that each cage contained up to five mice, in every
case corresponding to a mix from different experimental
groups. All animal procedures were in accordance with good
animal practice as defined by the relevant national/EU and
ARRIVE guidelines and the CEEA-CABIMER Experimental
Animal Committee, and all animal procedures were
approved by the corresponding committee (CEEA-2010-14).
Immunization protocol
Mice were immunized on day 0 with 5 or 50mg of Hsp70
(‘‘low’’ or ‘‘high’’ dose, respectively) and/or 1.06 or 10.6mg
of aSyn (‘‘low’’ or ‘‘high’’ dose, respectively). All prepara-
tions were diluted in PBS (ca. 50-fold dilution of the pre-
incubation mixtures) in the absence of added adjuvants.
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Mice were injected with a single 100mL s.c. shot in the
lumbar region. The same procedure was repeated on day 7.
On day 14, mice were sacrificed, and the spleen and 500–
700mL of blood, were extracted for analyses.
Determination of CD4þ, Treg and Teff cell
populations
Splenocytes were isolated from the spleen of immunized
mice by perfusing with 10mL with PBS after which
erythrocytes were lysed by osmotic shock. The number of
cells was determined by counting them in a hemocytometer
and 106 cells were labeled with anti-CD4-FITC, anti-CD25-
APC, and anti-Foxp3-PE, antibodies (BD Biosciences, San
Diego, CA, USA), by following the manufacturer’s instruc-
tions. Flow cytometry analysis was performed with FACS
Calibur cytometer and CellQuest Pro (BD Biosciences, San
Diego, CA, USA) software.
The Treg cell population was calculated as the percentage
of cells positive for CD4, CD25, and Foxp3 staining among
the CD4þ lymphocyte population. The Teff (non-regulatory)
cell population was calculated as the percentage of cells that
stained positively for CD4 and negatively for Foxp3 from the
CD4þ lymphocyte population (Supporting Information
Fig. S1).
In vitro stimulation of splenocytes and
determination of secreted cytokines
Splenocytes were isolated from the spleen of immunizedmice
after sacrifice, as previously described. 3# 106 cells from each
mouse were divided and cultured in three wells (of a 12-well
plate) in RPMI medium (BioWhittaker, Verviers, Belgium)
with 10% inactivated fetal bovine serum (FBS, BioWhittaker,
Verviers, Belgium). Each well was treated as follows: well 1,
medium alone (control); well 2, aSyn (20mg/ml); well 3,
lipopolysaccharide from Escherichia coli serotype 0127:B8
(LPS) (Sigma–Aldrich, St. Louis, USA) (0.5mg/mL). After
incubation for 24 h, supernatants were collected and centri-
fuged at 500 g for 5min to eliminate any remaining cells and
debris, and stored at"808C for subsequent cytokine assaying.
For quantifying IFN-g, IL-10, and IL-17 levels from
culture supernatants, specific ELISA kits, namely Mouse
IFN-gamma and Mouse IL-10 BD OptEIATM kits (BD
Biosciences, San Diego, CA, USA), and ELISA Development
Kit Murine IL17 (PreproTech, London, UK), were used
according to the manufacturer’s instructions.
Antibody content and cytokine measurement in
mouse sera
Blood samples extracted after sacrifice were left for 1 h at 48C
and 1h at RT to let them clot. After clot formation samples
were centrifuged at 21,000 g for 15min to obtain cell-free
serum, and stored at "808C for further analyses.
To assay the content of total IgM and IgG antibodies,
samples were diluted 1:240,000 in PBS and 100mL aliquots
were transferred to a 96-well plate well (MaxiSorp plate,
NUNC, Roskilde, Denmark) and incubated for 1 h at 378C.
Next, wells were washed three times with 350mL of PBST
(PBS, 0.05% Tween20) and blocked for 1 h with Assay
Diluent (BDBiosciences, SanDiego, CA, USA). After washing
as in the previous step, wells were incubated for 1 h at 378C
with anti-IgM-(Miltenyi, Bergisch Gladbach, Germany) or
anti-IgG- (Promega, Madison, WI, USA) -HRP conjugated
secondary antibodies diluted 1:4000 in Assay Diluent (BD
Biosciences, San Diego, CA, USA). Afterwards, wells were
washed five times with PBST, and 3,30,5,50-tetramethylbenzi-
dine (TMB) substrate reagent was added to determine the
antibody content by following the manufacturer’s instruc-
tions. To measure the anti-aSyn specific antibodies in the
serum samples, a similar protocol was followed but with some
modifications. MaxiSorp (NUNC, Roskilde, Denmark) plates
were coated with 1mg of aSyn diluted in 100mL of PBS in
each well and incubated for 1 h at 378C. After coating,
washing, and blocking steps were performed as described
above, and 1:40 diluted serum samples in Assay Diluent (BD
Biosciences, San Diego, CA, USA) were added and incubated
for 2 h at 378C. Detection of IgM and IgG antibodies was
performed as in the protocol described above. All samples
were analyzed in duplicate.
To determine the IFN-g and IL-10 levels, specific ELISA
kits, namely Mouse IFN-gamma and Mouse IL-10 BD
OptEIATM kits (BD Biosciences, San Diego, CA, USA), were
used according to the manufacturer’s instructions.
Statistical analyses
Statistical analyses were performed by using the IBM SPSS
Statistics 20 pack. For all parameters (T cell populations,
antibody determinations, and cytokine measurements), the
Kruskal–Wallis one-way analysis of variance was firstly
performed to evaluate the existence of significant differences
among the experimental groups. In order to determine the
differences between groups and to obtain the P values, the
non-parametric Mann–Whitney U test for two independent
samples was performed. Each group consisted of 5–7 mice
(n¼ 5–7). Statistically significant differences were those with
P< 0.05.
Results
Preparation and characterization of a monomeric
aSyn/Hsp70 complex
Based on our previous finding that recombinant human
Hsp70 chaperone interacts with monomeric aSyn in
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vitro [40], we chose human Hsp70 to evaluate our
immunization strategy with aSyn. In the preparation of
the aSyn/Hsp70 complex to be used in biochemical studies
as well as for immunization protocols, conditions favoring
Hsp70/substrate-binding and therefore, the formation of the
aSyn/Hsp70 complex, were chosen and applied for all
sample preparations (i.e., aSyn/Hsp70 mixture, aSyn and
Hsp70 proteins alone, and buffer/vehicle). For this, highly
purified aSyn and Hsp70 in buffer (50mM Tris pH 7.4,
150mM KCl, 2mM MgCl2) at a 1:1 molar ratio (or the
corresponding protein amount for samples with aSyn or
Hsp70 alone) were incubated at RT in the presence of 4mM
ATP for 2 h to induce the opening of the Hsp70 substrate
binding pocket, and for a further 2 h with ADP added to a
final concentration of 2.5mM to favor the formation of the
‘‘high affinity’’ Hsp70/substrate complex [37].
In order to evaluate the formation of an aSyn/Hsp70
complex, we subjected the incubated mixtures to native
PAGE electrophoresis followed by Western blot with anti-
Hsp70 and anti-aSyn specific antibodies (Fig. 1A). Indeed,
we were able to detect a band shift in the lane corresponding
to the aSyn/Hsp70 sample, as compared to the lanes loaded
either with aSyn or with Hsp70 alone in both membranes
labeled with either specific antibodies (Fig. 1A). This
additional band, with apparently similar electrophoretic
migration distance in both labeling assays, should corre-
spond to a monomeric aSyn/Hsp70 complex.
To prove the interaction between monomeric aSyn and
Hsp70 and further demonstrate the formation of an Hsp70/
aSyn complex, we used surface plasmon resonance (Biacore,
GE Healthcare). This allowed to monitor the interaction, in
real time, between ATP-loaded Hsp70 and monomeric
a-Syn through the covalent immobilization of the chaper-
one onto flow cell 2 (active cell) of the sensor chip and the
injection of different a-Syn concentrations through both
active and reference, flow cells. Signals from the active cell
were corrected by subtracting signal from the reference one.
Our data showed that the immobilized ligand (Hsp70) was
able to specifically bind to the flowing analyte (monomeric
aSyn) in an ATP-containing buffer (Fig. 1B). None of the
sensorgrams could be fitted to a simple 1:1 Langmuir
binding model in order to calculate kinetic parameters (Ka
and Kd), probably because the interaction between both
molecules is more complex. Binding levels corresponding to
a section of the curves 5 sec before the end of the injections
were used to calculate the dissociation equilibrium constant
(KD). The steady state binding levels against analyte
concentration were plotted and fitted to a simple 1:1 fitting
model available in the Biacore Evaluation Software. A good
fit was obtained (x2 value of 0.0599 RU2), with a calculated
KD value of 192% 41mM (Fig. 1C), which should corre-
spond to the (ATP)Hsp70/aSyn complex, that is in the ‘‘low-
affinity’’ state [43]. Therefore, it can be inferred that the KD
value of the (ADP)Hsp70/aSyn complex induced in our
sample preparation for immunization, is lower than
190mM.
Restrained levels of anti-aSyn antibodies by
aSyn/Hsp70-immunization
To determine the ability of Hsp70 to act as a paradigm
‘‘chaperone adjuvant’’ with aSyn, we designed and tested
Figure 1. Characterization of the Hsp70-monomeric aSyn association
and complex formation. Native PAGE and Western blot analysis of
samples, by using anti-aSyn or anti-Hsp70 antibodies. In addition to the
bands corresponding to Hsp70 and aSyn proteins, a highly overlapping,
lower-mobility band can be seen in both Western blots, indicating the
formation of an Hsp70/aSyn complex. Bovine serum albumin was used as
a protein marker (indicated) (A). Binding of monomeric a-Syn to Hsp70
immobilized on a Biacore sensor chip. Sensorgrams illustrating dosage-
dependent binding of a-Syn to 1173 RU of immobilized Hsp70 are
represented (B). Steady-state concentration plot of a-Syn bound to Hsp70
5 seconds before the end of the analyte (a-syn) injection (C).
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two immunization protocols in mouse with a combination
of human aSyn and Hsp70 leading to the formation of a
moderate-affinity complex. For this purpose, highly puri-
fied, endotoxin-free recombinant Hsp70 and aSyn proteins
were used. Six to seven weeks old C57BL/6 male mice were
injected subcutaneously at days 0 and 7, with either ‘‘low’’
(5mg Hsp70 and/or 1.06mg aSyn) or ‘‘high’’ (50mg Hsp70
and/or 10.6mg aSyn) protein doses, or buffer (vehicle), and
maintaining a ca. 1:1 molar ratio for the mixture between
aSyn and Hsp70. One week after the booster injection, mice
were sacrificed and their spleen and whole blood were
extracted for further analyses.
In order to evaluate the aSyn-specific humoral response
resulting from the immunization protocol, we measured the
levels of anti-aSyn as well as total IgM and IgG antibodies in
serum (Fig. 2). For IgM, an increase in both the absolute
anti-aSyn and relative anti-aSyn (calculated as anti-aSyn
IgM/total IgM) antibodies was detected in the mouse groups
immunized with both doses of aSyn (ca. 35–50%), and with
‘‘low’’ Hsp70 (ca. 40%, for absolute IgM levels), while this
increase was virtually suppressed in the mouse group
immunized with the aSyn/Hsp70 combination (Fig. 2A, B).
A similar profile was observed for the measured IgG
antibodies, with similar trends that did not reach statistical
significance in absolute anti-aSyn and relative anti-aSyn
(calculated as anti-aSyn IgG/total IgG) antibodies, for the
‘‘aSyn’’ experimental group (Fig. 2C, D). Also in this case,
the anti-aSyn IgG antibody levels for both ‘‘aSyn/Hsp70’’
mouse groups were close to those in control mice, indicating
a differential ‘‘restrain’’ effect arising from immunization
with the aSyn/Hsp70 combination (Fig. 2B, D).
The regulatory (Treg) and effector (Teff) T cell
contents are affected by immunization
Because of the pivotal participation of CD4þ T cells in the
development of synucleinopathies and other misfolding
neurodegenerative diseases associated to chronic inflamma-
tion, we firstly compared the impact of immunizing mice
with vehicle, aSyn, Hsp70, or the aSyn/Hsp70 combination,
Figure 2. Humoral immune response characterization. Absolute anti-aSyn IgM (A) and relative anti-aSyn IgM (B) antibodies in serum from immunized
mice. Absolute anti-aSyn IgG (C) and relative anti-aSyn IgG (D) antibodies in serum. The relative content of specific antia-Syn IgMand IgG antibodieswere
calculated by dividing anti a-Syn IgM or IgG levels by the total corresponding antibody levels. AU: arbitrary units. Represented values are mean% S.E.M.
(n¼ 5–7). Asterisks correspond to statistically significant differences between one particular group and the “vehicle” group. Hash signs indicate
statistically significant differences between different groups. & /# P< 0.05, && /## P< 0.01.
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on the CD4þ cell populations within total splenocytes
(Supporting Information Fig. S1). Splenocytes were isolated
from immunized and sacrificed mice. The content of CD4þ
cells in total splenocytes as analyzed by flow cytometry
showed no significant differences between mouse groups
(data not shown).
Next, in order to compare the regulatory T (Treg) cell
population contents between the different mouse groups,
we quantitated the CD4þCD25þFoxp3þ-labeled cells in the
isolated splenocytes (Fig. 3A and Supporting Information
Fig. S1). Our results showed that at ‘‘low’’ concentrations
of immunogen, both the groups immunized with aSyn
and, to a lower degree, Hsp70, produced a significant
increase in the Treg percentage (15.7% 0.5% and 14.3%
0.5%, respectively), as compared to the mouse group
immunized with vehicle (control) (11.1% 1.0%). However,
this effect was not observed using the aSyn/Hsp70 mixture
(13.1% 1.2%), further indicating a differential effect of this
combination (Fig. 3A). The mice immunized with high
protein doses, on the other hand, did not show any
differences in the percentages of Treg cells compared to the
control mice.
Finally, in order to compare the content of the non-
regulatory/effector T (Teff) cell population in the isolated
splenocytes from the different mouse groups, we assayed the
percentage of Foxp3" (Fig. 3B and Supporting Information
Fig. S1). In this case, a significant reduction was measured in
the CD4þFoxp3" cell population content for the mouse
group immunized with a ‘‘low’’ dose of aSyn (22.8% 0.7%)
relative to the group injected with ‘‘vehicle’’ (38.1% 7.8%)
(Fig. 3B).
Differential immunoreactivity of aSyn- versus
LPS-pulsed splenocytes from immunized mice
Next, as a way to monitor possible aSyn-specific, hyper-/
hypo-immune responses, we measured cytokine release
profiles of cultured splenocytes isolated from immunized
mice after sacrifice. To this end the cultured cells from
the different experimental groups were pulsed either with
20mg/mL aSyn (to model the antigen specific immunore-
activity in vitro) or 1mg/mL LPS (to model non-specific/
polyclonal immunoreactivity in vitro) or, alternatively,
medium alone to determine the basal secretion levels, which
corresponds to a non-stimulated control (Fig. 4). In
particular, IFN-g and IL-17 as well as IL-10, were measured
in the supernatant collected after 24 h of incubation. Our
results show that splenocytes from mice immunized with a
‘‘high’’ dose of Hsp70 produced higher basal levels of IFN-g
(260% 97 pg/mL), as compared to splenocytes from mice
immunized with vehicle (Fig. 4A, left panel). On the other
hand, stimulation of cultured splenocytes with LPS induced
higher IFN-g secreted levels in cells from mice immunized
with ‘‘low aSyn’’ (15% 10 ng/mL) and the ‘‘low aSyn/
Hsp70’’ complex (20% 12 ng/mL), as well as with ‘‘high
Hsp70’’ (21% 9 ng/mL), as compared to the group immu-
nized with vehicle (Fig. 4A, central panel). However, the
largest induction of IFN-g was observed for cells isolated
from mice immunized with the ‘‘high aSyn/Hsp70’’
combination (36% 14 ng/mL) (Fig. 4A, central panel).
Notably, this higher general reactivity in the case of the
high dose of ‘‘aSyn/Hsp70’’ did not correlate with that
elicited by aSyn pulsing, as lower than basal levels of IFN-g
were measured as a result of aSyn-pulsing of splenocytes
for this group (Fig. 4A, left panel). Interestingly, lower values
of secreted IL-17 levels for the ‘‘low aSyn/Hsp70’’
(4.5% 0.17 pg/mL) and ‘‘high aSyn’’ (4.6% 0.11 pg/mL)
groups weremeasured as compared to the group immunized
with vehicle (5.4% 0.11 pg/mL), while an increase for the
Figure 3. Treg and Teff cell populations determination. Percentage of
Treg lymphocytes calculated as the percentage of cells positive for CD4,
CD25, and Foxp3 staining among the CD4þ lymphocyte population
(CD4þCD25þFoxp3þ) (A). Percentage of Teff lymphocytes calculated as
the percentage of cells with positive staining for CD4 and negative for
Foxp3 among the CD4þ lymphocyte population (CD4þFoxp3") (B).
Represented values are mean% S.E.M. (n¼5–7). Asterisks correspond to
statistically significant differences between one particular group and the
“vehicle” group. & P< 0.05, && P< 0.01.
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‘‘high Hsp70’’ group (6.1% 0.34 pg/mL) relative to the
control (5.0% 0.35 pg/mL was detected upon aSyn-pulsing
of splenocytes (Fig. 4B, left panel). On the other hand, no
significant differences in secreted IL-17 levels as a result of
LPS-stimulation of splenocytes were detected (Fig. 4B,
central, panel).
Regarding the immunomodulatory-linked cytokine IL-
10, splenocytes from all groups, except for the ‘‘low Hsp70’’
group, showed higher basal levels of IL-10 as compared to
splenocytes from mice immunized with vehicle (three- to
fivefold higher) (Fig. 4C, left panel). Pulsing splenocytes with
aSyn did not significantly alter this profile, except for the
‘‘low Hsp70’’ experimental group. Stimulation with LPS
produced more variability in IL-10 levels between the
various groups, although none of them reached statistical
significance as compared to the ‘‘vehicle’’ group (Fig. 4C,
central panel).
In order to normalize the aSyn-specific response to the
general splenocyte reactivity, we also analyzed the aSyn/LPS
ratio for the three cyokines measured (Fig. 4A, right panel).
A clear downregulation in the relative IFN-g secretion levels
upon challenge with aSyn could be observed for mice
immunized with the aSyn/Hsp70 combination at both doses
(three- to fivefold lower) and essentially unaltered relative
IL-17 levels (Fig. 4A, B, right panel). Conversely, significant
increases in the relative IL-10 levels upon aSyn challenge
were seen for the ‘‘high aSyn’’ and ‘‘high Hsp70’’ experi-
mental groups (fivefold higher), in addition to ‘‘high aSyn/
Hsp70’’ combination (threefold higher) (Fig. 4C, right
panel). Taken together, our results suggest that highly
reactive splenocytes that are hypo-responsive toward aSyn
andwhich display high IL-10 basal secreting levels, have been
uniquely generated by immunization of mice with the aSyn/
Hsp70 combination.
Figure 4. Cytokine release profile of splenocytes isolated from immunized mice. IFN-g (A), IL-17 (B), and IL-10 (C) levels were measured in supernatants
from cultured splenocytes isolated from immunized mice 24 h after treatment with aSyn (20mg/mL) or medium alone (left column), or with LPS
(0.5mg/mL) (center column). All cytokines were measured by ELISA. Pairwise aSyn/LPS ratios (right column) were calculated by dividing the cytokine levels
elicited by aSyn (pg/mL) by the corresponding cytokine response to LPS (pg/mL) for each mouse. The detection limit for the IL-10/IFN-g and IL-17 assay
kits were <30, and 4 pg/mL, respectively. Represented values are mean% S.E.M. (n¼ 5–7). Asterisks correspond to statistically significant differences
between one particular group and the “vehicle” group. Hash signs indicate statistically significant differences between different groups. & /# P< 0.05, && /##
P< 0.01.
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IFNg and IL-10 cytokine levels in serum indicate a
shift toward an immunomodulatory response in
aSyn/Hsp70-immunized mice
To evaluate the biological relevance in vivo of immunization
with the aSyn/Hsp70 complex, we assayed the levels of
IFN-g and IL-10 in serum obtained from immunized mice,
one week after the booster (Fig. 5). While virtually all mouse
groups showed no significant alterations in serum IFN-g
levels as compared to the vehicle group (12% 5 pg/mL), the
only significant change in this cytokine levels corresponded
to a threefold reduction for the ‘‘high aSyn/Hsp70’’
combination (3.6% 1.4 pg/mL) (Fig. 5A). Furthermore,
the only significant change in serum IL-10 levels observed
corresponded to a fourfold increase for the mouse group
immunized with ‘‘high aSyn/Hsp70’’ (28% 8 pg/mL) as
compared to mice immunized with ‘‘vehicle’’ (7.0% 1.8 pg/
mL) (Fig. 5A). Finally, we analyzed the pairwise serum IL-10/
IFN-g ratio (i.e., the IL-10/IFN-g measured levels for each
mouse) and compared the different experimental groups.
Remarkably, while the IL-10/IFN-g ratio for the ‘‘aSyn’’ and
‘‘Hsp70’’ groups remains close to that observed for the
‘‘vehicle’’ group, immunization of mice with the ‘‘aSyn/
Hsp70’’ combination at both doses produces a ca. eightfold
increase in this ratio (Fig. 5B). This unique effect of the
‘‘aSyn/Hsp70’’ combination is evidenced by the shift in the
serum IL-10/IFN-g relative levels, from a pro-inflammatory,
toward an immunomodulatory, profile (Fig. 5B).
Discussion
Over the last few years, immunotherapy has become an
expanding subject of study as a novel approach for the
treatment of neurodegenerative amyloid or misfolding
diseases, which remain essentially incurable. Accumulated
evidence highlights the central role in neurodegenerative
disorders of an uncontrolled cellular-mediated response that
could promote microglial activation and neuroinflamma-
tion, and ultimately lead to neurodegeneration [44, 45]. In
the present work we have combined the aggregating, IDP
protein aSyn and the full-length and functional Hsp70
chaperone to promote the formation of an aSyn/Hsp70
complex in vitro, and used it to vaccinate naive mice in the
absence of added adjuvants, to evaluate the resulting
immune response.
Our findings reveal that, while increased levels of anti-
aSyn IgM and IgG antibodies were produced by immuniza-
tion with aSyn and Hsp70 proteins alone, no such effect was
observed for the group vaccinated with the aSyn/Hsp70
combination, as compared to the control group. This unique
effect of aSyn/Hsp70 immunization to produce a restrained
anti-aSyn Ab response might be beneficial in the context of
PD as it has been suggested that anti-aSyn antibodies are
involved in the pathogenesis of the inherited form of the
disease [46–48]. Moreover, this feature could be especially
positive in the case of well-established autoimmune-related
neurodegenerative diseases such as Multiple Sclerosis (MS)
or Acute Motor Axonal Neuropathy, where elevated levels of
specific IgM and IgG antibodies directed against certain self
antigens have been shown to contribute to disease onset and
progression [49–53].
A similar trend was seen for the Treg and Teff cell
populations, in which the increments and reductions,
respectively, elicited by immunization with aSyn and
Hsp70 alone were restrained as a result of vaccination
with theaSyn/Hsp70 complex, again indicating a differential
Figure 5. IFN-g and IL-10 serum levels in immunized mice. IFN-g (gray)
and IL-10 (black) levels were measured in mouse sera one week after the
end of the immunization protocol, by ELISA (A). Pairwise IL-10/IFN-g ratios
were calculated by dividing the measured IL-10 cytokine level by the
measured IFN-g cytokine level for each mouse (B). The detection limit for
the IL-10 and FN-g assay kits were <30 pg/mL, Values are mean% S.E.M.
(n¼ 5–7). Asterisks correspond to statistically significant differences
between one particular group and the “vehicle” group. & P< 0.05,
&& P< 0.01.
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effect of the combined proteins and the formation of
an immunofunctional complex. This ‘‘buffering’’ of the
regulatory and non-regulatory/effector T cell content toward
basal levels as a result of immunization with the aSyn/Hsp70
complex – as opposed to immunization with both proteins
separately – could be potentially beneficial as it indicates a
capacity of the aSyn/Hsp70 immunization to restore or
maintain the Treg/Teff equilibrium in a disease, or pre-
onset, scenario.
Our results with cultured splenocytes from immunized
mice and subsequent challenge with aSyn or LPS, show
clearly that the aSyn-specific response is suppressed in the
case of vaccination with the aSyn/Hsp70 complex when
compared to vehicle-injected mice, as indicated by lower
aSyn-specific IFN-g and IL-17 relative secretion levels. Even
though other cells types present within splenocytes could
also respond to LPS stimulation, in addition to T cells – such
as B cells or dendritic cells – this result may reflect a lower
Th1/(Th17) response (a T cell-mediated response involving
the liberation of IFN-g and IL-17) toward aSyn as a result of
immunization with the aSyn/Hsp70 complex. In addition,
we found that this change is accompanied by higher basal
levels of secreted IL-10 that are not significantly altered when
challenged with aSyn.
Finally, we found that immunization with theaSyn/Hsp70
complex uniquely produced changes in the cytokine levels in
serum, consisting of a threefold reduction of IFN-g and a
fourfold increase of IL-10 absolute levels, as well as a sixfold
increase in the pairwise IL-10/IFN-g ratio, as compared to
vehicle-injected mice. These results clearly demonstrate that
the aSyn/Hsp70 combination produces a shift in the
peripheral immunity toward amodulatory – and presumably
protective – phenotype. This effect could potentially be
highly beneficial for treatment against misfolding diseases
and other neurodegenerative disorders, as the Th1/Th17
response has been linked to microglia polarization and/or
maintenance toward an M1 (classical) pro-inflammatory
phenotype [54, 55], which in turn has been shown to enhance
neurodegeneration in PD [17, 56, 57].
Overall, our results show that human Hsp70 chaperone
acts as a cell immunity adjuvant in combination with full-
length aSyn, producing a shift in the immune response
characterized by a restrained aSyn-specific humoral immu-
nity coupled to a modulatory/protective phenotype, in
immunized naive mice (Scheme 1). This shift toward an
immunomodulatory phenotype cannot, in principle, be
attributed to an increase in the Treg cell content, as similar
levels of Treg cells from spleen were measured in the aSyn/
Hsp70-immunized mice as compared to the control group.
Therefore, either a different quality of Treg cells, or the
engagement of other cell types such as NKT cells, B
lymphocytes or even dendritic cells, could potentially be
involved in this particular phenotype.
With the aim of minimizing the potential adverse effects
of immunization, such as exacerbated inflammation or
autoimmunity, two aSyn-based vaccination approaches
designed to bypass the antigen-specific cellular immunity
completely, while promoting a strong antigen-specific
humoral response, have been recently reported [23, 24].
In this work we describe an alternative strategy that is based
on the use of a combination of Hsp70 and aSyn to produce a
restrained anti-aSyn humoral response coupled to an
immunomodulatory phenotype. We propose that such a
combined response might simultaneously tackle two aspects
of PD pathobiology at the onset and progression stages:
firstly, an immunoregulatory phenotype in the periphery is
expected to exert a neuroprotective effect by communicating
and interacting with chronically activated microglia and
other immunocompetent cells in the CNS, and therefore
counteracting neuroinflammation. Secondly, it might
prevent the development of potentially detrimental poly-
clonal antibody responses against aSyn in an aSyn
overexpression or aggregation scenario, as opposed to a
specific antibody response directed toward toxic oligomeric
species or epitopes, of aSyn.
Furthermore, we suggest that the exploitation of the
differential immune response elicited by specific combina-
tions of aggregating proteins with immunoactive and
functional chaperones, or by certain HSP/aggregating
protein complexes, could be an effective means of suppres-
sion of the uncontrolled pro-inflammatory environment
associated to neurodegeneration in amyloid and other
misfolding disorders.
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